Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome

Interstitial cystitis/bladder pain Syndrome (IC/BPS) remains a mysterious and intricate urological disorder, presenting significant challenges to healthcare providers. Traditional guidelines for IC/BPS follow a hierarchical model based on symptom severity, advocating for conservative interventions a...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-08, Vol.25 (15), p.8015
Main Authors: Hu, Ju-Chuan, Tzeng, Hong-Tai, Lee, Wei-Chia, Li, Jian-Ri, Chuang, Yao-Chi
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
Arthritis
Axitinib
Biological products
Bladder
Clinical trials
Cystitis, Interstitial - therapy
Cytokines
Disease Models, Animal
Drug Delivery Systems
Drugs
Gene therapy
Health aspects
Health care industry
Humans
Hypoxia
Infections
Inflammation
Kinases
Medical research
Medicine, Experimental
Monoclonal antibodies
Pain
Pathophysiology
Patients
Stem cells
Transplantation
Tumor necrosis factor-TNF
Ulcers
Urinary Bladder - pathology
Urine
Vascular endothelial growth factor
Vehicles
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interstitial cystitis/bladder pain Syndrome (IC/BPS) remains a mysterious and intricate urological disorder, presenting significant challenges to healthcare providers. Traditional guidelines for IC/BPS follow a hierarchical model based on symptom severity, advocating for conservative interventions as the initial step, followed by oral pharmacotherapy, intravesical treatments, and, in refractory cases, invasive surgical procedures. This approach embraces a multi-tiered strategy. However, the evolving understanding that IC/BPS represents a paroxysmal chronic pain syndrome, often involving extravesical manifestations and different subtypes, calls for a departure from this uniform approach. This review provides insights into recent advancements in experimental strategies in animal models and human studies. The identified therapeutic approaches fall into four categories: (i) anti-inflammation and anti-angiogenesis using monoclonal antibodies or immune modulation, (ii) regenerative medicine, including stem cell therapy, platelet-rich plasma, and low-intensity extracorporeal shock wave therapy, (iii) drug delivery systems leveraging nanotechnology, and (iv) drug delivery systems assisted by energy devices. Future investigations will require a broader range of animal models, studies on human bladder tissues, and well-designed clinical trials to establish the efficacy and safety of these therapeutic interventions.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25158015